A Phase 2 Study of Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone in People With Amyloid Light Chain Amyloidosis

Share

Full Title

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis

Purpose

Amyloid light chain (AL) amyloidosis is a rare blood disease. It causes a buildup of an abnormal protein called amyloid in your heart and other organs and tissues. This can cause organ damage affecting how your organs work.
 
Researchers are finding the best dose and schedule of daratumumab to give with bortezomib, cyclophosphamide, and dexamethasone (D-VCd) in people with AL amyloidosis. The people in this study have AL amyloidosis and heart disease and/or are nonwhite. Daratumumab blocks a protein in the body that can prevent tumors from growing.

 

Who Can Join

To join this study, there are a few conditions. You must:

  • Have AL amyloidosis that has not been previously treated.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Heather Landau’s office at 646-608-3740.

Protocol

23-202

Phase

Phase II (phase 2)

Investigator

ClinicalTrials.gov ID

NCT05250973